Clinical Trial

Brugada Syndrome Substrate Characterization and Ablation

Study acronym: UNCOVERBrS
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 15, 2025 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Independent, single center, prospective study, to evaluate the efficacy, in consecutive BrS patients undergoing catheter ablation, at medium-long term follow-up after epicardial substrate homogenization. The target area is defined collecting signals using high density and high resolution mapping with equi-spaced electrode array. The ablation of abnormal fragmented prolonged low-frequency ventricular electrograms is performed by contact force catheter.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-12-01; most recent amendment 2025-08-12.
Status change: Not Yet Recruiting → Recruiting 2023-03-23
Trial Details
NCT Number NCT05643209
Lead Sponsor Maria Cecilia Hospital
Conditions Brugada Syndrome
Enrollment 20 participants
Start Date 2023-02-01
Primary Completion 2026-05-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-15